A motif specific to peptides that bind to the human class I major histocompatibility complex molecule HLA-A3 was identified by sequence analysis ofHPLC fractions containing endogenous peptides. Twenty-six different sequences were obtained, 19 of which were nonamers. The majority of these endogenous peptide sequences contained Leu at position (P)2, while most sequences contained Tyr or Lys at P9. In addition, Phe was shared by 16 sequences at P3. Synthetic peptides corresponding to endogenous peptide sequences were shown to bind to HLA-A3. The importance of Leu at P2 and Tyr or Lys at P9 ("anchor" residues) for peptide binding to HLA-A3 was demonstrated by the following results: (i) peptides GLFGGGGGY, GLFGGGGGK, and GLGGGGFGY, but not GLFGGGGGV, specifically bound to HLA-A3 and (iu) six nonapeptides from within the influenza A nucleoprotein, matrix, and polymerase proteins, selected for synthesis based upon their possession of P2 and P9 anchor residues, were shown to bind HLA-A3. In contrast, none of a set of eight peptides that bound to HLA-A2, or six that bound to HLA-B27, bound detectably to HLA-A3. These rmdings provide a rationale for the design and selection of peptides that can be recognized by HLA-A3-restricted T cells.
Since it became apparent that the function of class I major histocompatibility complex molecules depends upon the ability to bind small peptides (1) , one of the major goals of research in this area has been to establish the specificity of peptide binding for each class I molecule. The isolation of endogenous peptides from five murine and human class I molecules has led to the hypothesis that the endogenous peptide repertoire is largely determined by a limited set of amino acids (anchor residues) at certain positions in the peptides (2) (3) (4) . Molecular modeling of composite peptide structures in the HLA-A2 and HLA-B27 binding grooves (4) (5) (6) indicates that the side chains of anchor residues of the peptides protrude into pockets within the groove. In addition, peptides appear to align in the binding groove with the amino terminus in the A pocket and the carboxyl terminus in the F pocket (5, 7) . The exact location of anchor residues within peptides binding to particular class I molecules is most likely a reflection of HLA pocket accessibility and composition.
HLA-A3.1 is an allele found in ==-23% of Caucasians and 144% of Blacks (8) . A rare natural variant, HLA-A3.2, contains two amino acid substitutions at positions 152 (Glu to Val in pocket E) and 156 (Leu to Gln in pockets D and E) that have significant effects on recognition by virus-reactive and alloreactive cytotoxic T lymphocytes (9) . We have isolated endogenous peptides from HLA-A3.1 molecules obtained from a B-lymphoblastoid cell line and from transfected Hmy2.ClR cells. Peptides were also isolated from HLA-A3.1 molecules containing single amino acid substitutions at position 152 or 156, expressed in the Hmy2.ClR cells. Sequence analyses of these peptides revealed a characteristic motif of anchor residues that permits the identification of potential antigenic peptides. METHODS Cells. HLA-A3 molecules were isolated from the human plasma cell line Hmy2.ClR transfected with the HLA-A3.1, HLA-A3 L156Q, or HLA-A3 E152V genes (9) and from the Epstein-Barr virus-transformed human B-cell line GB.
Isolation of Peptides from HLA-A3. HLA-A3 complexes were isolated from detergent lysates of 1010 cells by immunoaffinity chromatography with the anti-HLA-A3 monoclonal antibody GAP.A3 (10) as described (2) . After extensive sequential washing with 10-20 ml each of phosphate-buffered saline containing octyl /3-D-thioglucopyranoside (OSGP, Calbiochem) at 15 tkg/ml (PBS/OSGP), 0.45 M NaCl/OSGP, and PBS/OSGP, the columns were eluted with 10 ml of 0.1 M NH4HCO3/OSGP at pH 11.6. The eluted fractions, containing 100-500 .ug (2) (3) (4) (5) (6) (7) (8) (9) nmol) of HLA complex, were neutralized immediately upon collection, dried, redissolved, and passed through a Centricon-10 microconcentrator (Amicon) or a C18 Sep-Pak cartridge (Waters) to remove the bulk of the intact proteins. The resulting partially purified extracts were fractionated by reversed-phase HPLC (see Fig. 1 
legend).
Analysis of Peptide Binding to Class I Heavy Chains. An HLA-A3.1 cDNA clone derived from an HLA-A3.1 B-lymphoblastoid cell line encoding aa 1-278 of HLA-A3.1 was amplified by the polymerase chain reaction using the primers 5'-CAGACCTGGGCGGGATCCCACTCCATGAGG-TATTTC-3' and 5'-GGGGAAGCTTCATTAGGAAGA-CAGCTCCCATCT-3' and inserted into the Escherichia coli expression plasmid pHN1+ as described (11) . HLA complexes were reconstituted by using HLA-A3 heavy chain (0.2 tkg) prepared from E. coli inclusion bodies, iodinated human P2-microglobulin (B2m; 12,000 cpm; specific activity, 0.1-1 X 1018 cpm/mol) and peptides (10 tug) in a final volume of 50 ,ul (11) . HLA-A2 and HLA-B27 heavy chains were prepared as described (11) . HLA complexes were analyzed by nondenaturing isoelectric focusing (11) . The stability of HLA-A3 (12) . Peptides were synthesized as described (12 
RESULTS
Separation of Endogenous Peptides. To obtain a source of HLA-A3-associated endogenous peptides, HLA-A3.1 and the mutant molecules HLA-A3 L156Q and HLA-A3 E152V were isolated from detergent lysates of transfected Hmy2.ClR cells or from the HLA-A3.1-positive, EpsteinBarr virus-transformed human B-cell line GB by immunoaffinity chromatography. After isolation ofthe lower molecular weight material (see Methods), the peptides were fractionated by reversed-phase HPLC. A representative HPLC fractionation of HLA-A3 L156Q-associated peptides is shown in Fig. 1 . The bulk of the peptides were eluted in the area between 19 and 34 min (fractions , and an enlarged view of this region is shown in Fig. 1 [2] [3] [4] [5] showed that all four of these synthetic peptides bound to HLA-A3 as evidenced by the incorporation of free 125I-p2m into the complex. As expected, the endogenous peptides did not bind to HLA-B27 or HLA-A2 ( Fig. 2 B and C ). An HLA-B27-binding peptide (SRY-WAIRTR) from influenza A nucleoprotein (aa 383-391) with an Arg at P2 and P9 did not bind to HLA-A3 ( Fig. 2A, terminal Lys did not (Fig. 2A, lane 9) . Although both the 9-residue and 10-residue forms ofthe endogenous peptide pn2 bound to HLA-A3 ( Fig. 2A, lanes 4 and 5) , the 10-residue version of pn2 formed a more stable complex (100 hr vs. 20 hr, Table 2 ).
Three Non-Glycine Amino Acids Are Sufficient for Stable Binding ofPeptide to HLA-A3. As the amino acids at P2 and P9 of the endogenous peptide sequences were the least variable, we hypothesized that P2 and P9 might be anchor positions. To determine whether residues at these hypothetical anchor positions were sufficient for binding of peptides to HLA-A3, we synthesized a "minimal" nonapeptide based upon a poly(Gly) backbone. Gly backbone residues were chosen for these peptides because they allow maximum peptide flexibility and contain no side chains capable of binding in the pockets of the peptide-binding groove. The nonapeptide GLGGGGGGY did not bind to HLA-A3 (Fig. 3, lane 2) . Two other peptides, GLFGGGGGY and GLFGGGGGK, each having an additional non-Gly residue, were selected for synthesis based upon the apparent predilection for Phe at P3 (see Table 1 ). Both of these peptides bound to HLA-A3 (Fig. 3, lanes 3 and 4) but not to HLA-A2 (lanes 9 and 10). The stability ofcomplexes formed with GLFGGGGGK [(L2F3K9)9] was slightly greater than that of complexes formed with GLFGGGGGY [(L2F3Y9)9I (6 hr vs. <1 hr, Table 2 ). A Gly-backbone peptide, GLF-GGGGGV, which contained the HLA-A2 peptide binding motif [(L2V9)9I (2) did not bind to HLA-A3 (Fig. 3, lane 5) but did bind to HLA-A2 (lane 7). Further studies have shown that GLGGGGFGY also binds to HLA-A3, indicating that the requirement for Phe at P3 is not stringent (data not shown).
Peptides from Influenza A Proteins Bind to HLA-A3. The value of the (L2,Y9/K9)9 anchor-residue motif in predicting HLA-A3-binding peptides was investigated by screening the influenza A nucleoprotein (NP), matrix (Ml), and RNA polymerase (Pol) protein sequences for nonamer subsequences that contained Leu at P2 and Tyr or Lys at P9. Six of 26 such sequences were synthesized and all 6 bound detectably to HLA-A3 (Fig. 4A, lanes 2 and 3, and Fig. 4B ). Four of them bound especially well. The importance of the P2 and P9 anchor-residue positions for determining peptide binding specificity was further investigated with the well-studied HLA-A2-speciflc influenza-A Ml peptide GILGFVFTL (aa 58-66). This peptide, as expected, failed to promote HLA-A3 complex formation (Fig. 4A, lane 4) . However, a substitution derivative of this peptide with Lys at P9, GILGFVFTK, chosen because it had good matches to the HLA-A3 motif, clearly was able to bind to HLA-A3 (lane 5). The HLA-B27-binding peptide SRY-WAIRTR was also converted into a peptide that bound to HLA-A3 by changing the Arg at P2 to Leu (lane 6). DISCUSSION Twenty-six amino acid sequences were obtained for endogenous peptides eluted from HLA-A3. The preferred length for these peptides appears to be nine residues, as indicated by 19 of the 26 peptide sequences that were obtained (Table 1) . Synthetic peptides corresponding to the sequences of several of the endogenous peptides bound to HLA-A3 in vitro, supporting the conclusion that these sequences are indeed representative of peptides that are bound to HLA-A3 in vivo.
The P2 and P9 anchor residues are of prime importance for HLA-A3 complex formation as indicated by the limited amino acid variability at these positions for HLA-A3-binding peptides ( Table 1 ). The value of the defined anchor residues at P2 and P9 for predicting peptide binding to HLA-A3 was investigated by screening influenza A protein sequences for segments that contained Leu (P2) followed seven residues later by Tyr or Lys (P9). Six such peptides were selected for synthesis and were shown to be capable of binding to HLA-A3 (Fig. 4) . In addition, HLA-A2 and HLA-B27 peptides can be converted to HLA-A3 binding peptides by substituting the appropriate anchor residues at these positions (Fig. 4A, lanes 5 and 6) ; however, the side chains of these anchor residues in themselves do not provide enough interaction for stable binding to the HLA-A3 heavy chain, as indicated by the failure of GLGGGGGGY to promote HLA-A3 complex formation (Fig. 3, lane 2) . The ability of GLFGGGGGY and GLFGGGGGK to promote HLA-A3 complex formation emphasizes the potential importance of the P3 side-chain interaction for peptide binding to HLA-A3. However, it is clear that a P3 Phe or Tyr is not necessary for peptides to bind to HLA-A3, as peptides lacking such P3 residues ( Fig. 2A, lane 8, and Fig. 4A , lanes 2 and 5) and GLGGGGFGY (data not shown) also bind. In these cases, other P3 side chains and/or the side chains of other peptide residues such as P6 or P7 may provide interactive forces capable of stabilizing peptide binding.
On the basis of models of peptide binding to HLA-A2 (6) and HLA-B27 (5), it is thought that the side chain of the residue at P2 contacts residues of the B pocket. There are no HLA-A2 4 4 ,32m H LA-A2 (A and B) . Two substitution derivatives of HLA-A2-and HLA-B27-binding peptides with HLA-A3 anchor residues at P2 and P9 were also tested for binding to HLA-A3 (A). Peptide GILGFVFTK is related to the HLA-A2-binding influenza-A Ml peptide GILGFVFTL (15) , and peptide SLYWAIRTR is related to the HLA-B27-binding influenza-A NP peptide SRYWAIRTR (15) . differences in amino acid residues between HLA-A2 and HLA-A3 in the B pocket that are thought to contribute directly to peptide binding. Therefore, it is not surprising to find that peptides binding to HLA-A2 and HLA-A3 share Leu or a closely related residue as the anchor residue at P2.
The side chain of the residue at P9 in the peptide is thought to bind in the F pocket (5-7). Since the F-pocket residues (Asp116, Thr143, Trp147, Leu81, Tyr123) thought to interact with peptides are identical in HLA-B27 and HLA-A3, one might expect the P9 anchor residues of peptides binding to these molecules to be identical, as appears to be the case for the P2 anchor residues in the case of HLA-A2 and HLA-A3. Of 11 HLA-B27 endogenous peptides identified to date (4), 7 (Fig. 4A, lane 6) , and in addition that an HLA-A3 antigenic peptide from the HIV envelope protein, RLRDLLLIVTR (14) , binds to HLA-A3 (data not shown), indicates that the failure to detect endogenous peptides with Arg at P9 is not due to a general inability of the HLA-A3 binding site to accommodate such peptides.
The majority of the peptides that bind to HLA-A3 are nonamers, but in two cases it is clear that the decapeptide is the preferred sequence. The HIV Nef decapeptide QVPLRP-MTYK (aa 73-82) bound to HLA-A3, but the nonapeptide lacking the carboxyl-terminal Lys did not ( Fig. 2A, lanes 8  and 9) . This result is consistent with the prior observation that only the decapeptide was capable of sensitizing target cells for lysis by HLA-A3-restricted, HIV-specific cytotoxic T cells (16) . The second example is that pn2a (KLYEKVY-TYK) formed a 5-fold more stable complex than pn2b (KLYEKVYTY) ( Table 2) .
To determine whether or not the source of the HLA-A3 molecules would influence the endogenous peptide repertoire, endogenous peptides were isolated from two different cell lines (Hmy2.ClR and GB) and from two HLA-A3 mutants (E152V and L156Q) expressed in the Hmy2.ClR cell line. We had anticipated that peptides isolated from HLA-A3.1, HLA-A3 E152V, and HLA-A3 L156Q might have characteristic differences since residues 152 and 156 face toward the peptide binding site (6) and mutations at these sites have been shown to affect recognition by cytotoxic T cells (9) . Models of the HLA-A2 (6) and HLA-B27 (5) peptide binding sites indicate that residues 152 and 156 are part of pocket E, which is believed to bind the side chain of P7. We observed that endogenous peptides eluted from HLA-A3.1 mutants contained more Phe or Tyr at P7, whereas the peptides eluted from wild-type HLA-A3.1 contained predominantly hydrophobic aliphatic residues at P7. Whether this is indeed representative of true differences in the P7 residues or whether this is a consequence of the relatively small number of peptides analyzed remains to be determined. In any case, synthetic peptides corresponding to pn2, pn4, and pn6, which were isolated from the HLA-A3 L156 mutant and contained Tyr or Phe at P7, bound to the HLA-A3.1 heavy chain.
In conclusion, a specific combination of anchor residues has been identified from HLA-A3 endogenous peptide sequences. This has allowed the prediction of peptides which are capable of binding to HLA-A3, providing a rationale for the design of HLA-A3-specific peptide-based vaccines.
